TSTickerStarGet alerts

AEMD 10-Q filed 2026-11-12 | Key takeaways

AEMD filed its 10-Q; the most relevant disclosure change is added Proposed Merger with North Immunology: On September 17, 2026, Aethlon entered a two-step merger agreement with North Immunology, Inc. and two wholly owned subsidiaries; the combined company is expected to operate under the name North Immunology, Inc. and focus on North Immunology's pipeline led by.

Share this story

Key takeaways

  • Proposed merger with North Immunology: Aethlon entered a two-step merger agreement on September 17, 2026 with North Immunology, Inc. and two wholly owned subsidiaries; the combined company is expected to be named North Immunology, Inc. and focus on North Immunology's pipeline led by NOR-101, with closing expected in the first quarter of calendar 2027 and the transaction not completed as of November 12, 2026.

  • Merger financing: North Immunology has entered agreements for a private placement expected to generate approximately $180 million in gross proceeds, including conversion of approximately $34 million of its outstanding convertible promissory notes, accrued interest, premiums and fees, and completion of that financing is a closing condition.

  • Dilution and contingent value rights: Existing holders are expected to receive contingent value rights tied to future monetization of the legacy Hemopurifier business that the filing states may have little or no value, while share issuance under the Merger Agreement is expected to substantially dilute existing ownership and voting interests.

  • Liquidity: Cash and cash equivalents were $6,486,639 at September 30, 2026 and management believes existing cash funds the reduced operating plan for at least twelve months even if the merger is not consummated; approximately $500,000 of at-the-market capacity remains.

  • Workforce reductions and lease wind-down: Reductions implemented near the end of the second fiscal quarter produced $84,125 of accrued severance, aggregate potential severance obligations are approximately $1.5 million, and office, laboratory and manufacturing leases expire March 2027 and are not intended to be renewed.

  • Capital structure: A 1-for-5 reverse stock split was effected July 31, 2026, authorized common shares were increased from 20,000,000 to 200,000,000 on October 7, 2026, the 2020 Equity Incentive Plan authorization rose by 100,000 shares, and July 2026 common warrants became exercisable October 1, 2026.

  • Clinical trial progress: The Australian oncology trial treated a second participant in Cohort 3 during the quarter and remained ongoing across three clinical sites, with the first two cohorts producing preliminary biomarker observations that are not stated to demonstrate clinical efficacy.

Key metrics

Total operating expensesThree months ended September 30, 2026
$2,675,028Increase of approximately $1,165,000, or 77.2%, from $1,509,830
Operating lossThree months ended September 30, 2026
($2,675,028)Loss widened from ($1,509,830) in the three months ended September 30, 2025
Net lossThree months ended September 30, 2026
($2,617,507)Net loss increased from ($1,487,100) in the three months ended September 30, 2025
Basic and diluted loss per shareThree months ended September 30, 2026
($2.60)($18.70) in the three months ended September 30, 2025, retroactively adjusted for the 1-for-5 reverse stock split
Total operating expensesSix months ended September 30, 2026
$4,254,231Increase of approximately $952,000, or approximately 29%, from $3,302,220
Net lossSix months ended September 30, 2026
($4,165,419)($3,248,958) in the six months ended September 30, 2025
Basic and diluted loss per shareSix months ended September 30, 2026
($5.97)($53.27) in the six months ended September 30, 2025
Research and development expensesThree months ended September 30, 2026
$481,000$294,000 in the three months ended September 30, 2025

Disclosure changes

  • Proposed Merger with North Immunology

    On September 17, 2026, Aethlon entered a two-step merger agreement with North Immunology, Inc. and two wholly owned subsidiaries; the combined company is expected to operate under the name North Immunology, Inc. and focus on North Immunology's pipeline led by NOR-101, with closing expected in the first quarter of calendar 2027 and not completed as of November 12, 2026.

    The transaction would shift the combined company from the Hemopurifier program to North Immunology's pipeline and requires stockholder, registration and Nasdaq approvals.
  • Risks Related to the Proposed Merger with North Immunology, Inc.

    Item 1A adds merger-specific risks covering closing conditions, the effect of a failure to complete, substantial dilution of existing stockholders, contingent value rights that may have little or no value, and Merger Agreement restrictions on business activities and alternative transactions while the merger is pending.

    Existing holders face potential loss of ownership percentage, payment uncertainty on the CVRs, and reduced strategic flexibility during the pendency of the merger.
  • North Immunology pre-closing private placement

    North Immunology has entered into agreements for a private placement expected to generate approximately $180 million in gross proceeds, including the conversion of approximately $34 million of outstanding convertible promissory notes, accrued interest, premiums and fees; completion of this financing is a condition to closing the merger.

    The financing determines the securities issued to North Immunology holders and financing investors, which drives the share count and dilution of existing Aethlon stockholders.
  • Commitments and contingencies

    Aethlon will pay an M&A advisory fee of approximately $1.0 million upon consummation, may be required to pay North Immunology a $300,000 termination fee under specified circumstances, and has executive employment agreements with change-in-control severance provisions representing approximately $1.5 million of potential obligations; no liabilities were recorded because recognition criteria were not met.

    These amounts become payable only on closing or on specified termination events and would consume cash in scenarios where the merger does not complete.
  • Workforce reductions and operating cost reductions

    In anticipation of the merger transition, the company implemented workforce reductions near the end of the second fiscal quarter and reduced operating expenditures, retaining personnel needed for corporate and regulatory compliance and the Australian oncology clinical trial; accrued severance was $84,125 at September 30, 2026.

    The reduced cost structure supports the company's twelve-month liquidity assessment and, if the merger is not consummated, avoids the severance and advisory success-fee obligations tied to closing.
  • Liquidity and going concern

    Cash and cash equivalents were $6,486,639 at September 30, 2026 and working capital was $5,582,635; management believes existing cash funds the reduced operating plan for at least twelve months from issuance of the financial statements even if the merger is not consummated, and expects the combined company to have sufficient resources for at least twelve months after closing.

    The assessment depends on the reduced cost plan and the merger outcome; resuming or expanding development beyond the current trial would require additional capital.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow AEMD in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert